好在，诺和诺德(NVO.US)随后公布的Wegovy销售表现让投资者放下心来。 减肥药市场仍拥有广阔的前景，多数机构预测该市场规模到本个十年末将达到千亿美元水平。而除了目前几乎垄断减肥药市场的礼来、诺和诺德之外，还有很多制药公司正在加紧研发其减肥药 ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...

The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

After easing diabetes and weight loss journey for many, the popular medications Ozempic and Wegovy have shown fresh promise ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

周三，诺和诺德公布了三季度业绩，减肥药Wegovy当季销售额超出预期。这一消息让投资者们松了一口气，因为其竞争对手礼来上周报告的减肥药销量令人失望。受此影响，美股诺和诺德盘前大涨5%。今年以来，由于减肥药火爆，诺和诺德股价一路走高，并于6月25日触及 ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Weight loss drugs like Ozempic and Wegovy may provide strong relief from severe osteoarthritis knee pain, new research finds.

生产“减肥神药”Wegovy的丹麦药厂诺和诺德 (Novo Nordisk)第三季盈利273.01亿丹麦克朗 ...

丹麦制药公司诺和诺德公司报告称，其肥胖药物Wegovy在第三季度的销售强劲，超过了分析师的预期。销售额达到173亿丹麦克朗（约合24.9亿美元），比上一季度增长48%，高于预期的159亿克朗。